{
  "id": "mhgap#risk_safety_933fe150",
  "content": "66\nEPI 2\nEPILEPSY Management\nTABLE 1: Antiepileptic medications (cont.)\nMEDICATION ORAL DOSING SIDE EFFECTS CONTRAINDICATIONS / CAUTIONS\nPHENOBARBITAL Adults: Common: Sedation, hyperactivity in children, ataxia, Contraindicated in patients with acute intermittent porphyria.\nStart 60 mg daily in 1-2 divided doses. nystagmus, sexual dysfunction, depression.\nIncrease weekly by 2.5-5 mg (maximum 180 mg daily). Lower doses for patients with kidney or liver disease.\nSerious: Liver failure (hypersensitivity reaction), decreased\nChildren: bone mineral density.\nStart 2-3 mg/kg daily in 2 divided doses.\nIncrease weekly by 1-2 mg/kg daily depending\non tolerance (maximum 6mg daily).\nPHENYTOIN Adults: Common: Sedation, confusion, dizziness, tremor, motor Lower doses for patients with kidney or liver disease.\nStart 150-200 mg daily in two divided doses. twitching, ataxia, double vision, nystagmus, slurred\nIncrease by 50 mg daily every 3-4 weeks speech, nausea, vomiting, constipation.\n(max 400 mg daily).\nSerious: Hematologic abnormalities, hepatitis,\nChildren: polyneuropathy, gum hypertrophy, acne, lymphadeno-\nStart 3-4 mg/kg daily in 2 divided doses. pathy, increase in suicidal ideation.\nIncrease by 5 mg/kg daily every 3-4 weeks\n(maximum 300 mg per day).\nWomen who are pregnant or\nbreastfeeding: Avoid\nOlder adults: Use lower doses",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "high",
    "topics": [
      "risk_safety",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General â€” Risk Safety 66\nEPI 2\nEPILEPSY Management\nTABLE 1: Antiepileptic medications (cont.)\nMEDICATION ORAL DOSING SIDE EFFECTS CONTRAINDICATIONS / CAUTIONS\nPHENOBARBITAL Adults: Common: Sedation, hyperactivity in children, ataxia, Contraindicated in patients with acute intermittent porphyria.\nStart 60 mg daily in 1-2 divided doses. nystagmus, sexual dysfunction, depression.\nIncrease weekly by 2.5-5 mg (maximum 180 mg daily). Lower doses for patients with kidney or liver disease.\nSerious: Liver failure (hypersensitivity reaction), decreased\nChildren: bone mineral density.\nStart 2-3 mg/kg daily in 2 divided doses.\nIncrease weekly by 1-2 mg/kg daily depending\non tolerance (maximum 6mg daily).\nPHENYTOIN Adults: Common: Sedation, confusion, dizziness, tremor, motor Lower doses for patients with kidney or liver disease.\nStart 150-200 mg daily in two divided doses. twitching, ataxia, double vision, nystagmus, slurred\nIncrease by 50 mg daily every 3-4 weeks speech, nausea, vomiting, constipation.\n(max 400 mg daily).\nSerious: Hematologic abnormalities, hepatitis,\nChildren: polyneuropathy, gum hypertrophy, acne, lymphadeno-\nStart 3-4 mg/kg daily in 2 divided doses. pathy, increase in suicidal ideation.\nIncrease by 5 mg/kg daily every 3-4 weeks\n(maximum 300 mg per day).\nWomen who are pregnant or\nbreastfeeding: Avoid\nOlder adults: Use lower doses 66\nepi 2\nepilepsy management\ntable 1: antiepileptic medications (cont.)\nmedication oral dosing side effects contraindications / cautions\nphenobarbital adults: common: sedation, hyperactivity in children, ataxia, contrain..."
}